

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ANALYTICA LIMITED</b>
<b>ABN</b>	<b>12 006 464 866</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Michael Monsour
<b>Date of last notice</b>	7th February 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	
<b>Date of change</b>	13th June 2018

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p><b><u>Ordinary Shares</u></b>  Dr Michael Monsour  • 3,257,921 Ordinary Shares  MPAMM Pty Ltd  • 55,859,731 Ordinary Shares  MP Monsour Medical Practice Pty Ltd  &lt;Superannuation Account&gt;  • 294,684,095 Ordinary Shares  Halonna Pty Ltd &lt; Monsour Family A/C  • 349,266,296 ordinary shares  <b><u>ALTOA – listed options</u></b>  • 2,500,000 MP Monsour Medical Practice Pty Ltd  &lt;Superannuation Account&gt;  • 14,166,666 Halonna Pty Ltd &lt; Monsour Family A/C  <b><u>Unlisted options</u></b>  MP Monsour Medical Practice Pty Ltd  &lt;Superannuation Account&gt;  • 13,000,000 unlisted options expiring 29 October 2018  • 20,000,000 unlisted options expiring 22 December 2021  <b><u>Unlisted options expiring May 2018</u></b>  Dr Michael Monsour  • 325,792  MPAMM Pty Ltd  • 5,585,973  MP Monsour Medical Practice Pty Ltd  &lt;Superannuation Account&gt;  • 29,468,409  Halonna Pty Ltd &lt; Monsour Family A/C  • 34,926,629</p>
<p><b>Class</b></p>	<p>Ordinary shares  Unlisted options</p>
<p><b>Number acquired/disposed</b></p>	<p>70, 306,803 ordinary shares acquired on conversion of 70,306,803 unlisted Options expiry of ALTOA – listed options  2,500,000 MP Monsour Medical Practice Pty Ltd&lt;Superannuation Account&gt;  14,166,666 Halonna Pty Ltd &lt; Monsour Family A/C</p>
<p><b>Number disposed</b></p>	<p>-</p>
<p><b>Value/Consideration</b>  Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$351,534</p>

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<p><b><u>Ordinary Shares</u></b> Dr Michael Monsour</p> <ul style="list-style-type: none"> <li>• 3,587,713 Ordinary Shares</li> </ul> <p>MPAMM Pty Ltd</p> <ul style="list-style-type: none"> <li>• 199,750,620 Ordinary Shares</li> </ul> <p>MP Monsour Medical Practice Pty Ltd &lt;Superannuation Account&gt;</p> <ul style="list-style-type: none"> <li>• 156,379,178 Ordinary Shares</li> </ul> <p>Halonna Pty Ltd &lt; Monsour Family A/C</p> <ul style="list-style-type: none"> <li>• 413,661,334 ordinary shares</li> </ul> <p><b><u>Unlisted options</u></b> MP Monsour Medical Practice Pty Ltd &lt;Superannuation Account&gt;</p> <ul style="list-style-type: none"> <li>• 13,000,000 unlisted options expiring 29 October 2018</li> <li>• 20,000,000 unlisted options expiring 22 December 2021</li> </ul>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Conversion of unlisted options

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<p><b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed</p>	-
<b>Interest acquired</b>	-
<b>Interest disposed</b>	-
<p><b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation</p>	-
<b>Interest after change</b>	-

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ANALYTICA LIMITED</b>
<b>ABN</b>	<b>12 006 464 866</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ross Mangelsdorf
<b>Date of last notice</b>	7th February 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Tambien Pty Ltd and Edmonmont (Mr Mangelsdorf is a director, shareholder, trustee)
<b>Date of change</b>	13th June 2018

**Appendix 3Y**  
**Change of Director's Interest Notice**

<p><b>No. of securities held prior to change</b></p>	<p><b><u>Ordinary Shares</u></b>  Ross James Mangelsdorf  • 271,763 Ordinary Shares  Ross Mangelsdorf &amp; Jennifer Margaret Mangelsdorf  • 271,763 Ordinary Shares  Tambien Pty Ltd  • 51,280,967 Ordinary Shares  Edmonmont  • 29,336,826 ordinary shares</p> <p><b><u>ALTOA</u></b>  Ross James Mangelsdorf  • 2,370 ALTOA  Ross Mangelsdorf &amp; Jennifer Margaret Mangelsdorf  • 2,370 ALTOA  Tambien Pty Ltd  • 2,230,255 ALTOA  Edmonmont  • 380,000 ALTOA</p> <p><b><u>Unlisted options</u></b>  • 10,000,000 unlisted options expiring date 29 October 2018  • 10,000,000 unlisted options. Expiry date 22 December 2021  • 10,000,000 unlisted options expiring 30 November 2022 with an exercise price of \$0.013 (Tambien Pty Ltd)</p> <p><b><u>Unlisted options expiring May 2018</u></b>  Ross James Mangelsdorf  • 27,176  Ross Mangelsdorf &amp; Jennifer Margaret Mangelsdorf  • 27,176  Tambien Pty Ltd  • 6,734,846  Edmonmont  • 4,533,684</p>
<p><b>Class</b></p>	<p>Ordinary Shares  Unlisted options</p>
<p><b>Number acquired</b></p>	<p>8,627,140 ordinary shares on conversion of 8,627,140 options</p>
<p><b>Number disposed</b></p>	<p>Lapsing of 2,695,742 options  Lapsing of 2,614,995 options ALTOA</p>

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$43,136
<b>No. of securities held after change</b>	<p><b>Ordinary Shares</b></p> <p>Ross James Mangelsdorf</p> <ul style="list-style-type: none"> <li>• 298,939 Ordinary Shares</li> </ul> <p>Ross Mangelsdorf &amp; Jennifer Margaret Mangelsdorf</p> <ul style="list-style-type: none"> <li>• 298,939 Ordinary Shares</li> </ul> <p>Tambien Pty Ltd</p> <ul style="list-style-type: none"> <li>• 58,015,811 Ordinary Shares</li> </ul> <p>Edmonmont</p> <ul style="list-style-type: none"> <li>• 31,174,770 ordinary shares</li> </ul> <p><b>Unlisted options</b></p> <ul style="list-style-type: none"> <li>• 10,000,000 unlisted options expiring date 29 October 2018</li> <li>• 10,000,000 unlisted options. Expiry date 22 December 2021</li> <li>• 10,000,000 unlisted options expiring 30 November 2022 with an exercise price of \$0.013 (Tambien Pty Ltd)</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of unlisted options

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	-
<b>Interest acquired</b>	-
<b>Interest disposed</b>	-

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	-
<b>Interest after change</b>	-

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

---



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>ANALYTICA LIMITED</b>
<b>ABN</b>	<b>12 006 464 866</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Peter B. Corr
<b>Date of last notice</b>	13 <sup>th</sup> June 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect interest
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	INOV8 LLC - Dr Corr is director and major shareholder
<b>Date of change</b>	13th June 2018
<b>No. of securities held prior to change</b>	INOV8 LLC Ordinary Shares - 360,790,157 Options 40,087,795 unlisted options with an exercise price of \$0.005 10,000,000 unlisted options with an exercise price of \$0.013 per option and expiring on 30 November 2022
<b>Class</b>	Unlisted options
<b>Number acquired</b>	-
<b>Number disposed</b>	Expiry of 40,087,795, unlisted options

---

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	INOV8 LLC Ordinary Shares - 360,790,157 10,000,000 unlisted options with an exercise price of \$0.013 per option and expiring on 30 November 2022.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	-
<b>Interest acquired</b>	-
<b>Interest disposed</b>	-
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	-
<b>Interest after change</b>	-

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

---